IASO Bio Presents Updated Long-Term Follow-Up Data for BCMA CAR-T FUCASO® (Equecabtagene Autoleucel) at IMS 2023

/PRNewswire/ -- IASO Bio, a biopharmaceutical company engaged in discovering, developing, manufacturing and marketing innovative cell therapies and antibody...

Related Keywords

Tongji ,Sichuan ,China ,Shanghai ,Nanjing ,Jiangsu ,Huazhong ,Hubei ,Chinese ,Lugui Qiu ,Adimab Incyte ,Chunrui Li ,Eli Lilly ,A Equecabtagene Autoleucel ,Equecabtagene Autoleucel ,Innovent Biologics ,Innovent Biologics Inc ,International Myeloma Society ,Huazhong University Of Science Technology ,Chinese Academy Of Medical Science Hematology Hospital ,Md Anderson Cancer Center ,Tongji Medical College ,China National Medical Products Administration ,Complete Response ,Abstract Code ,Myeloma Society ,Annual Meeting ,Refractory Multiple ,Chinese Academy ,Medical Science Hematology Hospital ,Tongji Hospital ,Huazhong University ,New Drug Application ,National Medical Products Administration ,Sintilimab Injection ,Bevacizumab Injection ,Adalimumab Injection ,Rituximab Injection ,Pemigatinib Oral Inhibitor ,Ramucirumab Injection ,Selpercatinib Capsules ,Equecabtagene Autoleucel Injection ,Tafolecimab Injection ,Cancer Center ,Iaso Bio ,